PMN310 going in the right directionEveryday more and more support seems to be coming out for targeting the oligomers in the treatment of AD. More public awareness just boosts PMN's direction and we will get alot more coverage when we start releasing data from our clinical trials. The timing is really working in our favour
https://neurosciencenews.com/amyloid-fibril-neuropharmacology-23207/